Novo Nordisk got European approval to move forward ... they expect the transaction to be completed by the end of 2024. New Jersey-based Catalent manufactures medicines for pharmaceutical companies ...

Novo Nordisk, already active in capital improvements to add manufacturing capacity to meet growing demand for its metabolic medicines, is now building infrastructure for the production of rare ...

Novo Nordisk CEO Lars Fruergaard Joergensen in December during a presentation of a new production site. The company's latest attempt at a weight loss drug, CagriSema, matched the bar set by a ...